Similarly, Lu et al. (2023) confirmed through in vitro and in vivo experiments that API (5, 50 mg/kg) alleviated NAFLD by inhibiting the NLRP3 inflammasome. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.